Comparative Pharmacology
Head-to-head clinical analysis: MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus RENESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus RENESE.
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs RENESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moexipril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing diuresis and reducing plasma volume.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
One tablet (7.5 mg moexipril / 12.5 mg hydrochlorothiazide or 15 mg moexipril / 25 mg hydrochlorothiazide) orally once daily.
Initial 2.5-5 mg orally once daily; increase by 2.5-5 mg every 2-4 weeks up to 20 mg/day as needed.
None Documented
None Documented
Moexiprilat (active metabolite) terminal half-life is approximately 2–9 hours (mean ~9 hours in hypertension; prolonged in renal impairment). Hydrochlorothiazide terminal half-life is 6–15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: Twice-daily dosing may be needed for 24-hour BP control; renal impairment requires dose adjustment.
13–15 hours; prolonged in renal impairment (CrCl <30 mL/min: up to 30–40 hours).
Moexipril is eliminated primarily by renal excretion (about 50% as unchanged drug and metabolites) and biliary/fecal excretion (about 50%). Hydrochlorothiazide is eliminated largely unchanged by renal excretion (≥95% via glomerular filtration and tubular secretion).
Renal: ~85% unchanged; fecal: ~15% (via bile).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic